Table 2. Clinicopathological characteristics of patients with curative GC according to the groups.
| Variables | Control group n=358 (%) |
COVID group n=46 (%) |
p |
|---|---|---|---|
| Sex | 0.672 | ||
| Female | 144 (40.2) | 20 (43.5) | |
| Male | 214 (59.8) | 26 (56.5) | |
| Age (years) | 0.954 | ||
| Mean (SD) | 62.4 (13) | 62.3 (9.3) | |
| Body mass index (kg/m2) | 0.687 | ||
| Mean (SD) | 24.5 (4.5) | 24.2 (4.2) | |
| Hemoglobin (g/dL) | 0.811 | ||
| Mean (SD) | 12.1 (2.1) | 12.0 (2.6) | |
| Albumin (g/dL) | 0.622 | ||
| Mean (SD) | 3.9 (0.5) | 4.0 (0.6) | |
| Neutrophil-lymphocyte ratio (NLR) | 0.135 | ||
| Mean (SD) | 2.82 (2.83) | 4.37 (6.83) | |
| Charlson-Deyo Comorbidity Index (CCI) | 0.154 | ||
| 0 | 233 (65.1) | 25 (54.3) | |
| ≥1 | 125 (34.9) | 21 (45.7) | |
| ASA (American Society of Anesthesiologists) | |||
| I/II | 144 (68.2) | 28 (60.9) | 0.321 |
| III/IV | 114 (31.8) | 18 (39.1) | |
| Lauren's type | 0.692 | ||
| Intestinal | 195 (54.5) | 22 (47.8) | |
| Diffuse/Mixed | 152 (42.5) | 23 (50) | |
| Not specified | 11 (3.1) | 1 (2.2) | |
| Tumor size (cm) | 0.663 | ||
| Mean (SD) | 4.6 (2.9) | 4.5 (2.9) | |
| pT | 0.489 | ||
| pT1/T2 | 152 (42.5) | 22 (47.8) | |
| PT3/T4 | 106 (57.5) | 24 (52.2) | |
| Number of dissected LN | 0.026 | ||
| Mean (SD) | 40.8 (18.7) | 47.4 (21.3) | |
| pN | 0.769 | ||
| pN0 | 163 (45.5) | 22 (47.8) | |
| pN+ | 195 (54.5) | 24 (52.2) | |
| pM | 0.574 | ||
| pM0 | 352 (98.3) | 45 (97.8) | |
| pM1 | 6 (1.7) | 1 (2.2) | |
| pTNM | 0.320 | ||
| I/II | 206 (57.5) | 30 (65.2) | |
| III/IV | 152 (42.5) | 16 (34.8) |
SD, standard deviation; LN, lymph node.